Pfizer - Q1 FY2026 Earnings Analysis
Pfizer delivered Q1 2026 revenues of $14.5 billion, up 5% year-over-year, beating expectations on top-line growth while adjusted diluted EPS of $0.75 declined 18% versus the prior-year quarter. Management reaffirmed full-year 2026 guidance of $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted diluted EPS.
Performance Highlights
Pfizer reported Q1 2026 revenues of $14.5 billion, a 5% year-over-year increase and 2% operational growth, with ex-COVID revenues expanding 7% operationally. Adjusted diluted EPS came in at $0.75, down 18% from $0.92 in Q1 2025, pressured by higher cost of sales and an elevated adjusted tax rate of 16.9% versus 7.8% a year ago.
The standout operating driver was the 22% operational revenue growth across Launched and Acquired Products, anchored by Padcev (+39%), Nurtec ODT/Vydura (+41%), Oncology biosimilars (+52%), and Lorbrena (+32%), demonstrating robust commercial momentum in oncology and neurology. These gains were partially offset by steep COVID-19 product declines, with Comirnaty down 59% and Paxlovid down 63% operationally, reflecting narrower vaccination recommendations and lower infection-driven demand.
Management Outlook and Forward Catalysts
Management reaffirmed all components of full-year 2026 guidance, targeting revenues of $59.5–$62.5 billion and adjusted diluted EPS of $2.80–$3.00, signaling confidence in the non-COVID portfolio's ability to absorb pandemic-era revenue erosion. With approximately 20 key pivotal studies on track to start in 2026 and a Phase 3 Vyndamax patent settlement extending exclusivity to mid-2031, Pfizer is actively reinforcing its long-term revenue base.
The central investor debate heading into Q2 centers on whether non-COVID growth and pipeline execution can sustainably offset the COVID revenue cliff and rising cost of goods, with bulls watching Padcev's MIBC label expansion and obesity pipeline progress via the Sciwind GLP-1 collaboration, while bears focus on the adjusted EPS compression trajectory, $1.5 billion of anticipated generic and biosimilar headwinds, and the absence of share repurchases as the company prioritizes de-leveraging.
Adjusted EPS vs. consensus breakdown — primary performance driver, segment revenue contribution, and gross margin trajectory relative to prior guidance...
Segment-by-segment revenue analysis, margin profile, and management commentary on demand trajectory vs. consensus range expectations...
Forward guidance implications for the sector, supply chain read-throughs, and investment implications for the broader competitive landscape...